Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kathrin Gregoritza"'
Autor:
Inn H. Yuk, Theo Koulis, Nidhi Doshi, Kathrin Gregoritza, Constanze Hediger, Vanessa Lebouc-Haefliger, Jamie Giddings, Tarik A. Khan
Publikováno v:
AAPS Open, Vol 8, Iss 1, Pp 1-22 (2022)
Abstract Hydrolytic degradation of the polysorbate 20 (PS20) surfactant in protein-based liquid formulations releases free fatty acids (FFAs), which can accumulate to form particles in drug products during real-time (long-term) storage. To identify f
Externí odkaz:
https://doaj.org/article/309e1482153a44eda5ca7dc1603040aa
Autor:
Andrea Allmendinger, Stefan Bleher, Kathrin Gregoritza, Anne Woehr, Ravuri S. K. Kishore, Victor Nicoulin, Si Kai Cai, Vanessa Lebouc, Matej Siketanc
Publikováno v:
Journal of pharmaceutical sciences. 111(3)
The occurrence of visible particles over the shelf-life of biopharmaceuticals is considered a potential safety risk for parenteral administration. In many cases, particle formation resulted from the accumulation of fatty acids released by the enzymat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d52429690e43bd0561254f959f19fd
https://pubmed.ncbi.nlm.nih.gov/34600939
https://pubmed.ncbi.nlm.nih.gov/34600939
Autor:
Steve Russell, Wenqiang Liu, Aadithya Kannan, Tamanna Shobha, Kyle Ritchie, Anthony Tomlinson, Miguel Saggu, Stephen Rumbelow, Jamie Giddings, Rosalynn Taing, Kathrin Gregoritza, Nidhi Doshi, Sandeep Yadav, Victor Nicoulin, Jeff Chu, Si Kai Cai, Lin Luis
Publikováno v:
Pharmaceutical research. 38(9)
To evaluate a modified high purity polysorbate 20 (RO HP PS20)—with lower levels of stearate, palmitate and myristate esters than the non-modified HP PS20—as a surfactant in biopharmaceutical drug products (DP). RO HP PS20 was designed to provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a21df0590584752abfffc3de701c783
https://pubmed.ncbi.nlm.nih.gov/34495486
https://pubmed.ncbi.nlm.nih.gov/34495486